Bristol-Myers Squibb's Yervoy awarded Prix Galien USA Discovery of the Decade

US pharma major Bristol-Myers Squibb (NYSE:BMY) received the Prix Galien USA Discovery of the Decade biotech award for Yervoy (ipilimumab), the company’s recombinant, human monoclonal antibody.

In honor of the 10th anniversary of the Prix Galien awards and recognizing this decade as one of history's most productive for research, this special honor distinguishes Bristol-Myers Squibb for its innovative discovery and development of Yervoy, which is now approved in more than 50 countries for treatment of unresectable or metastatic melanoma. The award is also a testament to Bristol-Myers Squibb’s efforts to establish immuno-oncology as a transformational approach to treating a wide range of malignancies.

The announcement was made during the tenth annual Prix Galien USA Awards Ceremony held last week in New York City. The Prix Galien Discovery of the Decade award, which is selected by a preeminent scientific committee that includes several Nobel Laureates, honors outstanding achievements in improving the human condition through the development of innovative therapies.